

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1645

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/462,682
		Filing Date	April 28, 2000
		First Named Inventor	FitzGerald, David J.
		Group Art Unit	1645
		Examiner Name	Portner, Virginia
Total Number of Pages in This Submission	1	Attorney Docket Number	015280310100

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Kenneth A. Weber	
Signature		
Date	September 28, 2001	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

September 28, 2001

Typed or printed name	Jo Ann Honcik Dallara	
Signature		Date
	September 28, 2001	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1274584 v1

RECEIVED
TECH CENTER 1600
OCT 09 2001



Hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On Sept. 28, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: J. Dallara

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FITZGERALD, David J.

Application No.: 09/462,682

Filed: April 28, 2000

For: PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS

Examiner: Portner, Virginia

Art Unit: 1645

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Madam:

In response to the office action mailed August 6, 2001, requesting restriction under 35 U.S.C. 121 and 372, Applicant elects Group I. Applicant further elects the species wherein the cell recognition domain is the PE domain and the non-native epitope comprises a cysteine-cysteine loop that comprises the non-native epitope. The following claims read on the elected species: 1-4, 7-18, and 24-38.

The Examiner suggests in paragraph 2, that each species lacks unity with other species. Applicant disagrees that all species are distinct from each other. For example, a common structure in many species is the non-native epitope domain, wherein a non-native epitope is located between two cysteine residues resulting in a loop structure of the non-native epitope within the chimeric immunogen. The following species share

#10
Harry
Oct. 20, 2001
PATENT
015280-310100US
E-057-97/1
RECEIVED
OCT 03 2001
TECH CENTER 1600/2900

FITZGERALD, David J.
Application No.: 09/462,682
Page 2

PATENT

the cysteine-cysteine loop as a common structural feature: the cysteine-cysteine loop, SEQ ID NO 3, SEQ ID NO 4, V3 loop of gp120 of HIV-1, V3 loop of gp120 of HIV-1 (>=8a.a.), V3 domain of HIV-1, ntPE-V3MN14, and ntPE-V3MN26. In addition, the species share other common structural features such as the translocation domain and the endoplasmic reticulum retention domain.

Applicant requests an interview with the Examiner, after allowable subject matter is identified, to discuss an appropriate scope of the claims.

Respectfully submitted,



Kenneth A. Weber
Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
ERS
SF 1269426 v1